Peptides for Fat Loss

The 'peptides for fat loss' category sits in a different conceptual space from clinical obesity medicine. Where obesity peptides target metabolic disease in clinical populations, body-recomposition peptides are studied in the context of athletes, bodybuilders, and biohackers — populations that already have low or moderate body fat and want further reduction without sacrificing lean mass.

The compounds in this space tend to act on different mechanisms than the GLP-1 incretins that dominate medical obesity: GH-axis stimulation (CJC-1295/ipamorelin, MOD-GRF, hexarelin), GH-fragment lipolysis (AOD-9604), mitochondrial metabolism (MOTS-c, 5-Amino-1MQ), and ghrelin-receptor activity for appetite control without GLP-1's gastrointestinal burden.

This hub focuses on the mechanism-by-mechanism breakdown of body-recomposition peptides — not as alternatives to medical obesity care, but as research compounds in their own category with their own physiology and their own evidence base.

The peptide approach to body recomposition emerged from the bodybuilding and physique communities in the 1990s and 2000s, when access to recombinant human growth hormone (rhGH) was tightly controlled and prohibitively expensive. Researchers and athletes began experimenting with the GHRH and GHRP analogs that had been developed pharmaceutically for clinical indications.

The CJC-1295 + ipamorelin stack became the canonical research configuration in the early 2010s — pairing a GHRH analog (CJC-1295) with a clean GHRP (ipamorelin) to produce amplified pulsatile GH release without the supraphysiologic spikes characteristic of exogenous rhGH.

AOD-9604 had a more conventional pharmaceutical development history — Metabolic Pharmaceuticals advanced it through phase 2b for obesity in the 2000s. It demonstrated modest weight-loss effects in human trials but was not advanced to phase 3, and it entered the research-peptide ecosystem as a niche lipolytic compound.

Mitochondrial-derived peptides (MDPs) like MOTS-c were discovered in the 2010s by the Cohen lab at USC, which identified short open reading frames within the mitochondrial genome encoding bioactive peptides. MOTS-c's effects on AMPK and metabolic flexibility have made it an active area of recomposition research.

5-Amino-1MQ is more recent — a small-molecule NNMT inhibitor (technically not a peptide but commonly grouped here) developed in the 2010s based on the discovery that nicotinamide N-methyltransferase overexpression in adipocytes drives obesity in animal models.

GH-axis peptides (CJC-1295 + ipamorelin, sermorelin, tesamorelin, hexarelin) stimulate endogenous growth hormone release. Elevated GH and IGF-1 drive lipolysis — particularly in visceral adipose tissue — while preserving or increasing lean mass. The pulse-amplification stack (GHRH + GHRP) is the dominant research configuration.

AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone (residues 176–191). It retains the lipolytic effect of GH on adipocytes without the IGF-1 elevation, theoretically isolating fat loss from the broader GH-axis effects on glucose and insulin sensitivity.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that acts on AMPK signaling — the same metabolic master switch activated by exercise and metformin. Research has examined effects on insulin sensitivity, mitochondrial biogenesis, and metabolic flexibility.

5-Amino-1MQ is a small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) — an adipose-tissue enzyme whose overexpression drives obesity in animal models. Inhibition shifts adipocytes toward a more metabolically active state.

Tesofensine is a triple monoamine reuptake inhibitor (not strictly a peptide, but commonly grouped here) developed initially for Parkinson's disease and repurposed for obesity research after weight loss emerged as a side effect.